MEDIA ADVISORY --- BIO 2001: Highlight of Events for Wednesday, June 27
| 7 - 8:00 a.m. Plenary Breakfast Ballroom 6 |
2001 Biotechnology Heritage Award, presented to Dr. Francis S. Collins, Director of the Human Genome Institute at NIH and Dr. J. Craig Venter, Celera Genomics Corporation. (Note: Collins and Venter will be available to the media immediately following the breakfast in room 5B.)
|
| 8:15 - 9:45 a.m. Food and Ag Track Session Upper Level, Room 2 |
The Global Trade Dilemma, led by Paul Drazek, President, DTB Associates, panel speakers will discuss how increasingly expensive regulations impede international trade, largely between developing countries. Speakers will review the current impacts of trade, including costs and barriers. (Note: Panelists will be available to the media immediately following the track session in room 5B.)
|
| 8:15 - 9:45 a.m. CommunicationsMezzanine Level, Room 16B |
Biotech in the Media - How Are We Doing?, chaired by Dan Eramian, Vice President, Communications, Biotechnology Industry Organization, a panel of reporters who cover the biotechnology industry will discuss the effectiveness of the industry in presenting itself and its case to the public with regards to the announcement of the Human Genome Project, the introduction of GMO crops and foods and the prescription drug debate, among other issues.
|
| 10:15 - 11:45 a.m. Food and Ag Track Session Upper Level, Room 2 |
Lack of Global Harmonization and Challenges for Developing Countries, chaired by L. Val Giddings, Vice President, Food and Agriculture, Biotechnology Industry Organization, academics from the U.S. and Africa address the impact of agricultural biotechnology for developing countries.
|
| 11 a.m. Press Conference Upper Level, Room 5B |
Israeli Export Institute: The Israeli Chief Scientist of the Israeli Ministry of Trade and Compugen Ltd., will give an overview of the biotechnology industry in Israel.
|
| 12 - 1:45 p.m. Plenary LuncheonBallroom 6 |
Naomi Judd, Grammy award-winning singer, and Alan Hobson, cancer survivor and Mt. Everest climber (Note: Judd and Hobson will be available to the media immediately following in room 5B.)
|
| 2- 3:30 p.m. Industrial and Environmental Track Session Upper Level, Room 3 |
Global Climate Change and Energy - Can Modern Biotechnology Provide Workable Solutions?, led by James S. McLaren, Ph.D., President, Inverizon International Inc., speakers will discuss the broad-ranging positive impacts that industrial biotechnology solutions can have on issues pertaining to our environment.
|
| 2- 3:30 p.m. Policy/Ethics Track Session UMezzanine Level, 16A |
Conserving Endangered Species in the Genomics Era, this session brings scientists working at the interface of genomics and conservation from the world-famous San Diego Zoo, the biotechnology industry and the Human Genome Project to present new research findings and initiatives for benefiting endangered species. Chaired by Oliver A. Ryder, Ph.D., Kleberg Genetics Chair, Center for Reproduction of Endangered Species.
|
| 2 - 3:30 p.m. Science Track Session Upper Level, Room 9 |
Hitting the Target - Accurate Drug Delivery, the panel of speakers, led by Paul Drayson, Ph.D., CEO. PowerJect Pharmaceuticals plc, has been chosen to provide a broad overview of the current state of the art in biotech drug delivery and will provide thoughtful, provocative insights into the challenges and opportunities ahead for the industry.
|
| 2 - 3:30 p.m. Science Track Session Upper Level, Room 10 |
Regenerative Medicine: Sustaining Human Health by Harnessing the Body's Regenerative Capabilities, Co-chairs Doros Platika, M.D., President and CEO, Curtis, Inc. and Daniel Hartmann, Faculty of Pharmacy, will discuss how regenerative medicine seeks to harness the body's inherent ability to repair damage caused by disease, trauma or age.
|
| 3:30 p.m. Press Conference Upper Level, Room 5B |
Biotechnology Industry Organization and Ardana Bioscience to Donate
|
|
4 - 5:30 p.m. |
Global Balancing Act: Intellectual Property Rights and the Plight of the Poor, Anne G. K. Solomon, Senior Adviser and Former Deputy Assistant Secretary of State for Science, Technology and Health, will lead a discussion about intellectual property rights (IPR) protection and its importance to the vitality of technological innovation and commercialization.
|
|
4 - 5:30 p.m. |
Cloning and Stem Cells: New Controversies, led by Michael J. Werner, Esq., Director, Federal Government Relations/Bioethics Counsel, Biotechnology Industry Organization, this session will examine the NIH policy to allow federal funding for research using stem cells, which is currently under review by the Bush administration.
|
|
4 - 5:30 p.m. |
Innovative Research and Infectious Diseases, a panel led by Gerald Yakatan, Ph.D., President and CEO, Avanir Pharmaceuticals, will discuss some of the cutting-edge research that could lead to treatments for infectious diseases such as hepatitis, herpes, malaria, HIV and the common cold.
|
|
2 - 3:30 p.m. |
The Future of DNA Microarrays and Bioinformatics in Research and Diagnostics, chaired by August Sick, Senior Manager, Business Development, Invitrogen Corporation, this session will present recent applications demonstrating the power of microarrays and advanced bioinformatics technologies in identifying differentially expressed biomarker genes.
|
|
2 - 3:30 p.m. |
Oversight of Gene Therapy: Protecting Patients and Promoting Research The FDA and NIH have recently formally issued plans that would dramatically change the regulatory environment for companies doing gene therapy experiments. This program, chaired by Michael J. Werner, Esq., Director, Federal Government Relations/Bioethics Counsel, Biotechnology Industry Organization, will discuss several important issues surrounding regulation in the industry.
|
|
2 - 5:30 p.m. |
Mergers & Acquisitions Symposium, chaired by Richard A. Leavitt, Principal, William Gallagher Associates Insurance Brokers, Inc., and Stephen Ferruolo, Shareholder, Heller Ehrman White & McAuliffe LLP, speakers on this panel will address the future of genomics and the information challenge it poses.
|
|
3 p.m. |
Florence Wambugu, Ph.D., Director, ISSA AfriCenter, Kenya, will discuss her book, "Modifying Africa: How Biotechnology Can Benfit the Poor and Hungry: A Case Study from Kenya."
|
|
4 p.m. |
MediChem/Neurocrine Announcement, MediChem (NASDAQ:MCLS) a Chicago-based drug discovery technology and services company, and Neurocrine Biosciences (NASDAQ: NBIX), a San Diego-based biopharmaceutical discovery and development company, will announce that they have entered into a two-year collaborative GPCR agreement in proteomics for new drug development.
|
|
4 - 5:30 p.m. |
Animal, Mineral or Vegetable: Which Model for Product Discovery, John A. Ryals, Ph.D., President and CEO, Paradigm Genetics, chairs a discussion about the utility of different gene-based discovery models that have influenced the success of the genomics industry.
|
|
4 - 5:30 p.m. |
The Impact of State Drug Price Control Schemes on Emerging Biotech Companies, Thomas C. Norton, Senior Vice President, SPECTRUM Science Public Relations, chairs a discussion of the consequences of state drug price control programs.
|
|
4 - 5:30 p.m. |
Managing Diabetes: Advances in Insulin Therapy from Novel Delivery Systems, Lars Karlsen, Senior Vice President, Head of Project Portfolio Managements, Novo Nordisk A/S, chairs a discussion of how recent advances in insulin delivery will improve patient compliance with insulin regimens and quality of life.
|
|
4 - 5:30 p.m. |
Raiders of the Lost Genome: Gene Analysis on the Post-Genome Era, chaired by Teresa W. Ayers, CEO and Director, Genomica, this panel will review and discuss a variety of new technologies that will facilitate the deciphering of genetic data and provide gene function information for product development.
|
|
4 - 5:30 p.m. |
Innovative Research and Infectious Diseases, a panel led by Gerald Yakatan, Ph.D., President and CEO, Avanir Pharmaceuticals, will discuss some of the cutting-edge research that could lead to treatments for infectious diseases such as hepatitis, herpes, malaria, HIV and the common cold.
|
|
4 - 5:30 p.m. |
Stopping Global Pandemics in the Track, chaired by Franklin Berger, Senior Analyst, JP Morgan.
|
About BIO
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtechNOW.
